Opus Genetics (IRD) Times Interest Earned (2020 - 2026)
Opus Genetics (IRD) reported Times Interest Earned of -$208.17 for Q1 2026, down 10.88% on a QoQ basis from -$187.75 in Q4 2025.
Opus Genetics (IRD) has 5 years of Times Interest Earned data on file, last reported at -$208.17 in Q1 2026.
- Quarterly Times Interest Earned changed N/A year-over-year to -$208.17 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$217.34 (changed N/A YoY) and the FY2025 annual result came in at -$299.22, changed N/A from the prior year.
- Times Interest Earned fell to -$208.17 in Q1 2026 per IRD's latest filing, from -$187.75 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$122.22 in Q3 2025 and bottomed at -$1301.6 in Q1 2022.
- The 3-year median for Times Interest Earned is -$208.17 (2026), against an average of -$610.85.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | -208.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -208.17 |
| Dec 31, 2025 | -187.75 |
| Sep 30, 2025 | -122.22 |
| Jun 30, 2022 | -1,234.50 |
| Mar 31, 2022 | -1,301.60 |
| Dec 31, 2021 | -3,075.00 |
| Dec 31, 2020 | -2.58 |
| Sep 30, 2020 | -10.88 |
| Jun 30, 2020 | -1.83 |
| Mar 31, 2020 | -4.94 |